Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
EIGR

EIGR - Eiger BioPharmaceuticals Inc Stock Price, Fair Value and News

12.50USD0.00 (0.00%)Delayed

Market Summary

EIGR
USD12.500.00
Delayed
0.00%

EIGR Stock Price

View Fullscreen

EIGR RSI Chart

EIGR Valuation

Market Cap

18.5M

Price/Earnings (Trailing)

-0.25

Price/Sales (Trailing)

1.29

EV/EBITDA

0.1

Price/Free Cashflow

-0.25

EIGR Price/Sales (Trailing)

EIGR Profitability

Operating Margin

99.83%

EBT Margin

-522.31%

Return on Equity

-490.11%

Return on Assets

-193.07%

Free Cashflow Yield

-404.01%

EIGR Fundamentals

EIGR Revenue

Revenue (TTM)

14.4M

Rev. Growth (Yr)

41.06%

Rev. Growth (Qtr)

18.51%

EIGR Earnings

Earnings (TTM)

-75.0M

Earnings Growth (Yr)

46.48%

Earnings Growth (Qtr)

25.38%

Breaking Down EIGR Revenue

Last 7 days

3.7%

Last 30 days

291.6%

Last 90 days

488.4%

Trailing 12 Months

-53.1%

How does EIGR drawdown profile look like?

EIGR Financial Health

Current Ratio

0.71

EIGR Investor Care

Shares Dilution (1Y)

0.29%

Diluted EPS (TTM)

-50.93

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023015.5M14.6M14.4M
202211.2M13.2M14.1M13.5M
202100012.1M

Tracking the Latest Insider Buys and Sells of Eiger BioPharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Nov 02, 2023
kayne richard a
bought
6,965
0.2977
23,398
-
Nov 01, 2023
kayne richard a
bought
27,970
0.2797
100,000
-
Oct 31, 2023
kawas leen
bought
6,374
0.261993
24,332
-
Oct 31, 2023
kayne richard a
bought
37,879
0.244636
154,841
-
Mar 17, 2023
mayer eldon c. iii
sold
-4,703
1.0703
-4,395
ex vp & chief commerc. officer
Jan 23, 2023
dietz thomas john
bought
71,580
1.4316
50,000
-
Dec 29, 2022
murray christine
sold
-6,104
1.2208
-5,000
-
Dec 22, 2022
dietz thomas john
sold
-26,302
1.169
-22,500
-
Dec 22, 2022
glenn jeffrey s
bought
127,950
1.2795
100,000
-
Aug 16, 2022
apelian david
sold
-49,030
9.8061
-5,000
-

1–10 of 50

Which funds bought or sold EIGR recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 16, 2024
TOTH FINANCIAL ADVISORY CORP
sold off
-100
-56.00
-
-%
May 16, 2024
JANE STREET GROUP, LLC
sold off
-100
-6,624
-
-%
May 15, 2024
RBF Capital, LLC
new
-
54,910
54,910
-%
May 15, 2024
Tower Research Capital LLC (TRC)
sold off
-100
-4,113
-
-%
May 15, 2024
RBF Capital, LLC
sold off
-100
-76,046
-
-%
May 15, 2024
MILLENNIUM MANAGEMENT LLC
sold off
-100
-18,217
-
-%
May 15, 2024
683 Capital Management, LLC
new
-
148,448
148,448
0.01%
May 15, 2024
683 Capital Management, LLC
sold off
-100
-471,450
-
-%
May 15, 2024
TWO SIGMA SECURITIES, LLC
sold off
-100
-12,846
-
-%
May 15, 2024
Tower Research Capital LLC (TRC)
new
-
9,750
9,750
-%

1–10 of 49

Are Funds Buying or Selling EIGR?

Are funds buying EIGR calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own EIGR
No. of Funds

Unveiling Eiger BioPharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jul 01, 2024
arkin moshe
3.58%
53,071
SC 13D/A
May 10, 2024
ameriprise financial inc
0.00%
0
SC 13G/A
Feb 14, 2024
ameriprise financial inc
16.91%
7,505,539
SC 13G/A
Feb 14, 2024
683 capital management, llc
4.7%
70,000
SC 13G/A
Dec 04, 2023
arkin moshe
10.09%
4,481,126
SC 13D/A
Nov 24, 2023
arkin moshe
10.09%
4,482,126
SC 13D
Nov 03, 2023
propel bio management, llc
9.91%
4,391,432
SC 13D/A
Oct 20, 2023
propel bio management, llc
9.86%
4,367,100
SC 13D
Sep 28, 2023
propel bio management, llc
10.9%
4,823,938
SC 13G/A
Aug 15, 2023
propel bio management, llc
5.40%
2,392,167
SC 13G

Recent SEC filings of Eiger BioPharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Jul 16, 2024
8-K
Current Report
Jul 10, 2024
8-K
Current Report
Jul 01, 2024
SC 13D/A
13D - Major Acquisition
Jul 01, 2024
8-K
Current Report
Jun 21, 2024
8-K
Current Report
Jun 14, 2024
8-K
Current Report
May 28, 2024
8-K
Current Report
May 10, 2024
SC 13G/A
Major Ownership Report
May 08, 2024
8-K
Current Report
May 02, 2024
8-K
Current Report

Peers (Alternatives to Eiger BioPharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.4B
6.8B
-9.08% -2.89%
-7.78
6.94
-64.45% -224.75%
30.1B
2.0B
54.57% 18.06%
-90.59
15.02
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.0B
2.5B
-0.07% -3.94%
77.72
6.46
13.74% 186.89%
14.8B
3.8B
7.23% 2.92%
19.84
3.93
8.58% 129.81%
MID-CAP
4.9B
107.9M
-5.14% -24.06%
-8.96
48.09
54.84% -28.31%
4.6B
524.1M
-5.19% 10.95%
-11.05
8.8
394.93% 39.61%
4.0B
251.0M
11.60% 13.99%
-13.6
16.05
73.58% -86.73%
3.5B
240.7M
20.06% -18.70%
-7.43
12.77
-1.03% -213.92%
2.9B
813.8M
19.30% -43.25%
-1.7K
3.6
56.43% 98.83%
1.9B
996.6M
0.36% 71.71%
-4.87
1.95
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
13.16% 23.83%
30.73
4.86
60.38% -34.49%
618.2M
881.7K
32.05% 709.09%
-18.31
481.06
-77.61% 33.36%
260.1M
4.2M
17.29% 54.94%
-2.08
62.54
-66.30% 48.24%
18.8M
2.1M
-4.39% -80.54%
-0.81
7.61
-13.45% 69.54%

Eiger BioPharmaceuticals Inc News

Latest updates
Marketscreener.com11 Jul 202403:49 am

Eiger BioPharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q1
Revenue18.5%3,803,0003,209,0004,643,0002,696,0004,024,0004,091,0002,673,0003,360,0003,039,0002,097,0003,646,000
Cost Of Revenue-100.0%-115,000-345,0001,231,000151,000110,000104,000318,000270,00053,000
Costs and Expenses-18.5%16,417,00020,137,00024,624,00027,167,00030,393,00024,171,00024,493,00024,274,00024,890,00020,458,00019,459,000
  S&GA Expenses-13.8%4,702,0005,454,0005,533,0008,301,0006,964,0007,027,0006,813,0005,984,0006,466,0005,886,0005,564,000
  R&D Expenses-20.3%11,614,00014,568,00019,401,00018,521,00022,198,00016,993,00017,570,00018,186,00018,106,00014,302,00013,842,000
EBITDA Margin13.3%-4.82-5.57-5.86-6.85-6.31-6.42-7.33-2.47---
Interest Expenses1.0%1,426,0001,412,0001,343,0001,220,0001,092,000934,000886,000900,000894,000880,000885,000
Income Taxes-2,000-2,000-3,000-17,0009,00018,00016,00011,00019,000
Earnings Before Taxes25.4%-13,452,000-18,030,000-20,693,000-25,141,000-27,111,000-21,867,000-22,634,000-21,750,000-22,207,000-19,163,00029,267,000
EBT Margin12.2%-5.22-5.95-6.19-7.18-6.60-6.72-7.68-2.79---
Net Income25.4%-13,454,000-18,030,000-20,695,000-25,138,000-27,111,000-21,884,000-22,643,000-21,768,000-22,223,000-19,174,00029,248,000
Net Income Margin12.2%-5.22-5.95-6.19-7.18-6.60-6.72-7.68-2.79---
Free Cashflow4.1%-13,955,000-14,554,000-22,052,000-22,471,000-20,667,000-21,753,000-18,459,000-16,898,000-19,260,000-20,460,000-
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-30.2%39.0056.0072.0099.0012014416415312614015717614414110388.0010512013393.00102
  Current Assets-30.7%38.0055.0070.0097.0011814215814710399.0011917013813597.0082.0010011412888.00102
    Cash Equivalents-7.5%25.0028.0023.0015.0026.0026.0037.0047.0022.0049.0065.0010829.0052.0063.0023.0039.0019.0058.0063.0061.00
  Inventory40.8%2.001.001.005.003.003.003.002.003.003.002.001.000.00--------
  Net PPE-7.4%1.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.000.000.000.00
Liabilities-6.9%53.0057.0057.0064.0065.0065.0061.0056.0054.0051.0048.0049.0049.0048.0045.0045.0049.0048.0045.0042.0036.00
  Current Liabilities222.5%53.0017.0017.0024.0025.0026.0022.0037.0030.0022.0016.0018.0017.0022.0016.0013.0017.0017.0013.0011.0010.00
  Long Term Debt-100.0%-41.0040.0040.0040.0039.0039.0019.0024.0029.0031.0031.0031.0025.0027.0031.0030.0030.0030.0030.0026.00
    LT Debt, Current-41.00------13.008.003.00---6.003.00------
    LT Debt, Non Current-100.0%-41.0040.0040.0040.0039.0039.0019.0024.0029.0031.0031.0031.0025.0027.0031.0030.0030.0030.0030.0026.00
Shareholder's Equity---15.0035.0055.0078.0010397.0072.0089.0010912695.0093.0058.0043.0056.0072.0088.0051.0067.00
  Retained Earnings-2.7%-512-498-480-459-437-412-384-363-340-318-296-277-306-287-272-256-241-224-205-188-171
  Additional Paid-In Capital0.1%498497496495493491489461413408406403402381330300298296294239238
Shares Outstanding0.3%1.001.001.001.001.001.001.001.001.001.001.00----------
Float---30.00---274---286---258---255--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations4.1%-13,954-14,554-22,035-24,005-22,247-20,560-21,744-18,459-16,765-19,260-20,384-14,933-15,515-14,108-15,822-17,740-14,971-14,591-15,170-18,882-12,502
  Share Based Compensation-34.2%6831,0387452,5421,8402,2222,2082,0471,9642,3302,0581,5491,4371,4451,4621,6291,3481,6491,4871,1951,511
Cashflow From Investing-36.8%11,99919,00029,84613,38321,79710,384-19,547-3,002-13,3333,299-22,89894,464-26,967-45,42926,95765234,619-24,874-43,07216,8569,070
Cashflow From Financing-53.3%7.0015.00-22.0041.00-60.00-88.0031,30145,8023,064160-72.0015.0019,35348,71729,04934431945053,2564,17147,767
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

EIGR Income Statement

2023-12-31
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenues [Abstract]  
Total revenue[1]$ 15,773,000$ 13,484,000
Costs and operating expenses:  
Cost of sales[1]24,0001,837,000
Research and development[1]62,331,00075,282,000
Selling, general and administrative[1]25,204,00029,105,000
Total costs and operating expenses[1]87,559,000106,224,000
Loss from operations[1](71,786,000)(92,740,000)
Interest expense[1](5,466,000)(4,132,000)
Interest income[1]2,208,0001,082,000
Other (expense) income, net[1]87,000(963,000)
Loss before provision for income taxes[1](74,957,000)(96,753,000)
Provision for income taxes[1]6,00023,000
Net loss$ (74,963,000)[1]$ (96,776,000)[2]
Net loss per common share:  
Basic (in USD per share)[1]$ (50.78)$ (69.74)
Diluted (in USD per share)[1]$ (50.78)$ (69.74)
Weighted-average common shares outstanding:  
Basic (in shares)[1]1,476,2471,387,632
Diluted (in shares)[1]1,476,2471,387,632
Product revenue, net  
Revenues [Abstract]  
Total revenue[1]$ 15,523,000$ 12,734,000
Other revenue  
Revenues [Abstract]  
Total revenue[1]$ 250,000$ 750,000
[1]All periods presented have been retroactively adjusted to reflect the 1-for-30 reverse stock split effected on January 5, 2024. Refer to Note 1for further information
[2]All periods presented have been retroactively adjusted to reflect the 1-for-30 reverse stock split effected on January 5, 2024. Refer to Note 1for further information

EIGR Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents[1]$ 25,440$ 25,798
Short-term debt securities[1]073,150
Accounts receivable, net[1]1,6821,749
Inventories, net[1]1,5562,853
Prepaid expenses and other current assets[1]9,16113,985
Total current assets[1]37,839117,535
Property and equipment, net[1]627696
Other assets[1]3601,908
Total assets[1]38,826120,139
Current liabilities:  
Accounts payable[1]2,1158,975
Accrued liabilities[1]9,96615,655
Current portion of operating lease liabilities[1]84491
Current portion of long-term debt[1]41,1190
Total current liabilities[1]53,28425,121
Debt, net[1]039,625
Operating lease liabilities[1]083
Total liabilities[1]53,28464,829
Commitments and contingencies (Note 12)[1]
Stockholders’ (deficit) equity:  
Common stock, $0.001 par value, 200,000,000 shares authorized as of December 31, 2023 and 2022; 1,479,483 and 1,469,149 shares issued and outstanding as of December 31, 2023 and 2022, respectively[1]11
Additional paid-in capital[1]497,866492,802
Accumulated other comprehensive loss[1](169)(300)
Accumulated deficit[1](512,156)(437,193)
Total stockholders’ (deficit) equity[1],[2](14,458)55,310
Total liabilities and stockholders’ (deficit) equity[1]$ 38,826$ 120,139
[1]All periods presented have been retroactively adjusted to reflect the 1-for-30 reverse stock split effected on January 5, 2024. Refer to Note 1for further information.
[2]All periods presented have been retroactively adjusted to reflect the 1-for-30 reverse stock split effected on January 5, 2024. Refer to Note 1for further information
EIGR
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
 CEO
 WEBSITEeigerbio.com
 INDUSTRYBiotechnology
 EMPLOYEES56

Eiger BioPharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Eiger BioPharmaceuticals Inc? What does EIGR stand for in stocks?

EIGR is the stock ticker symbol of Eiger BioPharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Eiger BioPharmaceuticals Inc (EIGR)?

As of Thu Jul 18 2024, market cap of Eiger BioPharmaceuticals Inc is 18.51 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EIGR stock?

You can check EIGR's fair value in chart for subscribers.

What is the fair value of EIGR stock?

You can check EIGR's fair value in chart for subscribers. The fair value of Eiger BioPharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Eiger BioPharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EIGR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Eiger BioPharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether EIGR is over valued or under valued. Whether Eiger BioPharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Eiger BioPharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EIGR.

What is Eiger BioPharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 18 2024, EIGR's PE ratio (Price to Earnings) is -0.27 and Price to Sales (PS) ratio is 1.39. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EIGR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Eiger BioPharmaceuticals Inc's stock?

In the past 10 years, Eiger BioPharmaceuticals Inc has provided -0.458 (multiply by 100 for percentage) rate of return.